Our management team at AOP Orphan is composed of highly skilled experts whose careers and educational background are mostly in the natural sciences. They are a strong representation of the competence and professionalism that is found in each of our employees.
Led by a Board with longstanding experience in the pharmaceutical Industry:
Mag. Andreas Steiner, Chief Executive Officer and chairman of the board, an economist by education brings both inside views from the pharmaceutical industry as well as hospital management,
Dr. Rudolf Widmann, founder of the company, pharmacist by education with deep knowledge and passion for rare diseases treatments and research,
Dr. Günther Krumpl, medical doctor, pharmacologist, Associate Professor and entrepreneurial pioneer in the pharmaceutical industry,
Dr. Georg Fischer, medical doctor by education who also brings a longstanding experience in business development, which comprises new markets, international medical affairs and health technology.
The Board Members and the Executives, a team of highly educated experts, together form the Executive Management Team.
Most of them graduated in natural science and have acquired extensive research experience from both university institutions and industry research facilities. However, what binds them all together is not their common scientific background but rather their passion for fighting Orphan Diseases.
It is this passion that drives our management team and all our employees to fully commit themselves to developing and producing efficient drugs that can effectively fight Orphan Diseases and enhance the quality of the patient’s life to the greatest extent possible.
"AOP Orphan is the European pioneer in Orphan Diseases unconditionally committed to bringing not only drugs but full treatment support to patients with rare diseases."
"AOP Orphan having international expertise in pharmaceutical and clinical development as well as distribution and marketing of drugs in the rare disease area offers flexible solutions for in- and out-licensing partnerships."
"As a company, we are small enough to be really close to our patients, yet we are large enough to be able to provide them high-quality, personalized customer care."
"AOP Orphan commitment doesn't end at the company door. We live it - no matter where we are and when we are needed."
"AOP Orphan has successfully developed a number of innovative treatment options in recent years. To arrive at these, our thinking is guided above all by patient needs."
"Finding solutions for apparently impossible tasks, always focusing on the patients with a deep appreciation of their disease experience makes AOP Orphan a unique partner."
"To provide patients with effective drugs COLLABORATION is the key for success- within and between pharmaceutical industry and academia."
"Every day we at AOP Orphan consolidate our knowledge, expertise and energy to ensure that the patients get necessary treatments available notwithstanding the market complexity and challenges."
"AOP Orphan is fully dedicated to develop new treatments for patients with rare diseases. Everyday we do our best to understand and to serve the patients needs!"
"As an agile international team we strive for ambitious goals. This requires alignment across countries and functions as well as each one of us feeling accountable for the end result. Together we make a difference, and AOP Orphan a great place to work."
"AOP Orphan is an agile company operating worldwide via own local enterprises and partnerships. Each country has its own regulations that apply to drug research and development, manufacturing, marketing and post marketing activities - to name a few. At AOP Orphan we do our best to keep up the high standards at every step for the health and safety of the patients!"
"The development of a new drug can take between 8-15 years and can cost millions of euros from its discovery to the successful commercialization. To achieve this company needs not only stamina but also financial stability and effectiveness is indispensable. Our lean financial structure, enduring profitability, positive cash-flow and transparent, efficient controlling provides a solid financial basis for further company development, scientific discoveries and new therapies to ensure a benefit for the patient.”